EUVIMEDEUVIMED entdecken
Crossref

Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer

Joo-Young Byun iD, Ayobami Aiyeolemi, Aiham Qdaisat iD, Chanhyun Park iD

Cancer · 2024

DOI: 10.1002/cncr.35424 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer, 2024. Verfasst von Joo-Young Byun und 3 weiteren Autor:innen. Beteiligte Einrichtung: Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA. Hauptthemen laut MEDLINE: Carcinoma, Non-Small-Cell Lung, Venous Thromboembolism, Protein Kinase Inhibitors, Lung Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 58 Literaturangaben. Gefördert von: Korea Health Industry Development Institute.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Venous thromboembolism (VTE) risk is higher among patients with non–small cell lung cancer (NSCLC) and specific subgroups, including the elderly, but little is known about the VTE risk of different generations of epidermal growth factor receptor–tyrosine kinase inhibitors (EGFR‐TKIs) and whether the risk differs by demographic characteristics. This study aims to compare the risk of VTE (deep venous thromboembolism [DVT]; pulmonary embolism [PE]) between a third‐generation EGFR‐TKI and first/second‐generation EGFR‐TKIs and stratify VTE risk by sex, age, and race/ethnicity in third‐generation EGFR‐TKI users.

Methods

Via the 2006–2019 Surveillance, Epidemiology, and End Results–Medicare database, this retrospective cohort study included older patients (aged ≥65 years) with advanced NSCLC who initiated on a third‐generation EGFR‐TKI ( n = 493) and first/second‐generation EGFR‐TKIs ( n = 1036). We estimated the hazard ratio (HR) and its 95% confidence interval (95% CI) with the Cox proportional hazards model.

Results

A third‐generation EGFR‐TKI had a significantly higher VTE risk than first/second‐generation EGFR‐TKIs (HR, 1.26 [95% CI, 1.01–1.57]; p = .037), with an elevated risk in males (HR, 2.16 [95% CI, 1.47–3.19]; p < .001), patients aged ≥75 years (HR, 1.38 [95% CI, 1.04–1.83]; p = .026), and non‐Hispanic Whites (HR, 1.46 [95% CI, 1.10–1.95]; p = .010). Males consistently showed a significantly higher risk of DVT (HR, 2.49 [95% CI, 1.29–4.80]; p = .007) and PE (HR, 2.00 [95% CI, 1.29–3.11]; p = .002). A significantly higher risk of DVT (HR, 1.54 [95% CI, 1.00–2.37]; p = .050) and PE (HR, 1.47 [95% CI, 1.06–2.05]; p = .021) was shown in patients aged ≥75 years and non‐Hispanic Whites, respectively. Among third‐generation EGFR‐TKI users, non‐Hispanic Whites had a significantly higher risk of VTE (HR, 2.04 [95% CI, 1.03–4.02]; p = .041) and PE (HR, 2.88 [95% CI, 1.24–6.70]; p = .014) than non‐Hispanic Asian/Pacific Islanders.

Conclusions

Close monitoring of VTE events in high‐risk patients is essential to promote early diagnosis and treatment.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Carcinoma, Non-Small-Cell LungVenous ThromboembolismProtein Kinase InhibitorsLung NeoplasmsErbB ReceptorsHumansMaleAgedFemaleRetrospective StudiesAged, 80 and overSEER ProgramRisk FactorsPulmonary EmbolismUnited StatesTyrosine Kinase Inhibitors

Stichwörter der Autor:innen

epidermal growth factor receptor–tyrosine kinase inhibitornon–small cell lung cancerosimertinibpharmacoepidemiology studyvenous thromboembolism

Substanzen

Protein Kinase InhibitorsErbB ReceptorsEGFR protein, humanTyrosine Kinase Inhibitors

Autor:innen und Institutionen

  • Health Outcomes Division, College of Pharmacy, The University of Texas at Austin, Austin, Texas, USA.
  • School of Pharmacy, Sungkyunkwan University, Suwon, South Korea.
  • Division of Internal Medicine, Department of Emergency Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA.

ORCID-Profile: Joo-Young Byun, Aiham Qdaisat, Chanhyun Park

Förderung

  • Korea Health Industry Development Institute

Zitieren

APA

Byun, J. Y., Aiyeolemi, A., Qdaisat, A., & Park, C. (2024). Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. https://doi.org/10.1002/cncr.35424

Vancouver

Byun JY, Aiyeolemi A, Qdaisat A, Park C. Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer. Cancer. 2024. doi:10.1002/cncr.35424

BibTeX
@article{Byun2024,
  author = {Byun, Joo-Young and Aiyeolemi, Ayobami and Qdaisat, Aiham and Park, Chanhyun},
  title = {Association between epidermal growth factor receptor–tyrosine kinase inhibitors and venous thromboembolism among older patients with advanced non–small cell lung cancer},
  journal = {Cancer},
  year = {2024},
  doi = {10.1002/cncr.35424}
}
Kostenlos starten →